Mylan Partner Mabion Withdraws Rituximab In EU

US Firm Had Been Hopeful Of Launch This Year

 
• By Dean Rudge
Science_Lab
Mabion says it will now apply for rituximab for "full, commercial scale" • Source: Shutterstock

More from Biosimilars

More from Products